1. Home
  2. RVNC vs BTA Comparison

RVNC vs BTA Comparison

Compare RVNC & BTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVNC
  • BTA
  • Stock Information
  • Founded
  • RVNC 1999
  • BTA 2006
  • Country
  • RVNC United States
  • BTA United States
  • Employees
  • RVNC N/A
  • BTA N/A
  • Industry
  • RVNC Biotechnology: Pharmaceutical Preparations
  • BTA Trusts Except Educational Religious and Charitable
  • Sector
  • RVNC Health Care
  • BTA Finance
  • Exchange
  • RVNC Nasdaq
  • BTA Nasdaq
  • Market Cap
  • RVNC 546.4M
  • BTA N/A
  • IPO Year
  • RVNC 2014
  • BTA N/A
  • Fundamental
  • Price
  • RVNC $5.20
  • BTA $10.58
  • Analyst Decision
  • RVNC Buy
  • BTA
  • Analyst Count
  • RVNC 10
  • BTA 0
  • Target Price
  • RVNC $10.86
  • BTA N/A
  • AVG Volume (30 Days)
  • RVNC 2.3M
  • BTA 21.9K
  • Earning Date
  • RVNC 11-06-2024
  • BTA 01-01-0001
  • Dividend Yield
  • RVNC N/A
  • BTA 5.22%
  • EPS Growth
  • RVNC N/A
  • BTA N/A
  • EPS
  • RVNC N/A
  • BTA N/A
  • Revenue
  • RVNC $251,178,000.00
  • BTA N/A
  • Revenue This Year
  • RVNC $20.36
  • BTA N/A
  • Revenue Next Year
  • RVNC $31.66
  • BTA N/A
  • P/E Ratio
  • RVNC N/A
  • BTA N/A
  • Revenue Growth
  • RVNC 40.23
  • BTA N/A
  • 52 Week Low
  • RVNC $2.30
  • BTA $8.59
  • 52 Week High
  • RVNC $9.90
  • BTA $10.62
  • Technical
  • Relative Strength Index (RSI)
  • RVNC 38.45
  • BTA 44.66
  • Support Level
  • RVNC $5.08
  • BTA $10.58
  • Resistance Level
  • RVNC $5.41
  • BTA $10.66
  • Average True Range (ATR)
  • RVNC 0.19
  • BTA 0.06
  • MACD
  • RVNC -0.01
  • BTA -0.02
  • Stochastic Oscillator
  • RVNC 38.00
  • BTA 8.33

About RVNC Revance Therapeutics Inc.

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.

Share on Social Networks: